• 1. An amorphous carbon nitride/NiO/CoN-based composite: a highly efficient nonprecious electrode for supercapacitors and the oxygen evolution reaction?
  Huifang Yang,Haoran Guo,Peidong Fan,Xinpan Li,Wenlu Ren,Rui Song Nanoscale, 2020,12, 7024-7034
• 2. An aqueous ammonia sensor based on an inkjet-printed polyaniline nanoparticle-modified electrode
  Karl Crowley,Eimer O'Malley,Aoife Morrin,Malcolm R. Smyth,Anthony J. Killard Analyst, 2008,133, 391-399
• 3. An analysis of the WTC fires using CIB correlations and simple modeling
  JGQuintiere
• 4. Acentric and chiral heterometallic inorganic–organic hybrid frameworks mediated by alkali or alkaline earth ions: synthesis and NLO properties
  Huabin Zhang,Shaowu Du CrystEngComm, 2014,16, 4059-4068
• 5. An artificial enzyme cascade amplification strategy for highly sensitive and specific detection of breast cancer-derived exosomes?
  Huiying Xu,Lu Zheng,Yu Zhou,Bang-Ce Ye Analyst, 2021,146, 5542-5549

Introduction to 7-Bromo-2,2-difluoro-1,3-dioxaindan-4-amine (CAS No. 2231233-77-3)

7-Bromo-2,2-difluoro-1,3-dioxaindan-4-amine is a highly specialized organic compound that has garnered significant attention in the field of pharmaceutical chemistry and medicinal research. This compound, identified by its unique Chemical Abstracts Service (CAS) number 2231233-77-3, belongs to a class of molecules known for their versatile applications in drug development. The structural features of this compound, particularly the presence of a 7-bromo substituent and a 2,2-difluoro group within a dioxaindan framework, make it a promising candidate for further exploration in synthetic chemistry and biological activity studies.

The significance of this compound lies in its potential utility as an intermediate in the synthesis of more complex pharmaceutical agents. The dioxaindan core is a bicyclic structure that has been widely studied for its pharmacological properties, including antimicrobial and anti-inflammatory effects. The introduction of halogen atoms, such as bromine and fluorine, further enhances the reactivity and functionalization possibilities of this molecule, opening up new avenues for drug design.

In recent years, there has been a growing interest in the development of fluorinated compounds due to their improved metabolic stability and bioavailability. The 2,2-difluoro moiety in 7-Bromo-2,2-difluoro-1,3-dioxaindan-4-amine contributes to these desirable properties, making it an attractive scaffold for medicinal chemists. Additionally, the presence of an amine group at the 4-position provides a site for further chemical modifications, allowing for the attachment of various pharmacophores to enhance biological activity.

The synthesis of 7-Bromo-2,2-difluoro-1,3-dioxaindan-4-amine involves multi-step organic reactions that require precise control over reaction conditions and reagent selection. Advanced synthetic techniques, such as cross-coupling reactions and palladium-catalyzed transformations, are often employed to construct the desired molecular framework. These synthetic strategies not only highlight the complexity of working with such compounds but also showcase the ingenuity of modern chemical synthesis.

One of the most compelling aspects of this compound is its potential application in the development of novel therapeutic agents. Researchers have been exploring its use in targeting various diseases by modulating its chemical structure to achieve specific biological outcomes. For instance, studies have shown that derivatives of dioxaindan can exhibit significant inhibitory effects on certain enzymes and receptors involved in pathological processes. The bromine substituent further enhances the compound's potential as a lead molecule by providing a handle for selective functionalization.

The role of computational chemistry and molecular modeling has been instrumental in understanding the behavior of 7-Bromo-2,2-difluoro-1,3-dioxaindan-4-amine at both the molecular and cellular levels. These computational approaches have enabled researchers to predict binding affinities, metabolic pathways, and potential side effects before conducting expensive experimental trials. This integration of computational methods with traditional wet chemistry has accelerated the drug discovery process significantly.

In conclusion, 7-Bromo-2,2-difluoro-1,3-dioxaindan-4-amine (CAS No. 2231233-77-3) represents a fascinating example of how structural complexity can be leveraged to develop innovative pharmaceutical solutions. Its unique combination of functional groups and its potential as a building block for more complex drugs make it a valuable asset in medicinal chemistry research. As our understanding of molecular interactions continues to evolve, compounds like this one are likely to play an increasingly important role in addressing unmet medical needs.

• 332062-08-5(Fmoc-S-3-amino-4,4-diphenyl-butyric acid)
• 1270529-38-8(1,2,3,4,5,6-Hexahydro-[2,3]bipyridinyl-6-ol)
• 2680771-01-9(4-cyclopentyl-3-{(prop-2-en-1-yloxy)carbonylamino}butanoic acid)
• 2098070-20-1(2-(3-(Pyridin-3-yl)-1H-pyrazol-1-yl)acetimidamide)
• 1444113-98-7(N-(3-cyanothiolan-3-yl)-2-[(2,2,2-trifluoroethyl)sulfanyl]pyridine-4-carboxamide)
• 941977-17-9(N'-(3-chloro-2-methylphenyl)-N-2-(dimethylamino)-2-(naphthalen-1-yl)ethylethanediamide)
• 2138166-62-6(2,2-Difluoro-3-[methyl(2-methylbutyl)amino]propanoic acid)
• 89640-58-4(2-Iodo-4-nitrophenylhydrazine)
• 1449132-38-0(3-Fluoro-5-(2-fluoro-5-methylbenzylcarbamoyl)benzeneboronic acid)
• 2034271-14-0(2-(1H-indol-3-yl)-N-{[6-(thiophen-2-yl)-[1,2,4]triazolo[4,3-b]pyridazin-3-yl]methyl}acetamide)